

Sophie E Berends

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3944985/publications.pdf>

Version: 2024-02-01

14
papers

365
citations

1162889

8
h-index

1125617

13
g-index

14
all docs

14
docs citations

14
times ranked

593
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2680-2684.	1.1	4
2	Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 106-118.	1.1	18
3	Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 145-154.	0.6	61
4	Population pharmacokinetics of infliximab in children with juvenile idiopathic arthritis. <i>Therapeutic Drug Monitoring</i> , 2021, Publish Ahead of Print, .	1.0	1
5	Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 289-294.	1.0	13
6	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 15-37.	1.6	91
7	Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 885-891.	1.3	8
8	Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 997-1006.e6.	0.6	86
9	Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019, 46, 543-551.	0.8	8
10	Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 700-706.	0.6	16
11	Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1544-1551.	1.1	26
12	Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 202-211.	1.0	26
13	Effectiveness and safety of switching IBD patients from the originator to the biosimilar infliximab. <i>The Cochrane Library</i> , 2018, , .	1.5	0
14	Golimumab for moderate to severe ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 401-406.	1.4	7